Clinical Trial

Cost-effectiveness, Impact of a Workplace-based Intervention to Reduce Occupational Sitting Time in Office-based Workers

Study acronym: ISKE
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 9, 2024 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to examine the impact and cost effectiveness of a workplace-based intervention aimed at reducing prolonged occupational sitting among office-based workers. The study will be conducted in three phases. Phase I: is an Integrative review on economic evaluations of workplace-based interventions for reducing occupational sitting time. Phase II: is a secondary analysis of register data within the Northern Finland Birth Cohort 1966 (NFBC-1966). This is aimed at evaluating the association between prolonged sitting time with societal and/or organization economic perspective across different occupational categories at midlife. Phase III will be a Randomized Control Trial (RCT) of an office-based intervention designed to reduce prolonged occupational sitting time. The sample for the RCT will be 140 office-based workers - 70 participants will be enrolled in the control group whilst 70 participants will be enrolled within the intervention group. The study will be conducted from 2021 to 2025. An article-based dissertation will be completed at the end of the study, this will be mainly based on four articles that will be published in international peer reviewed journals.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-24.
Trial Details
NCT Number NCT06149364
Lead Sponsor University of Helsinki
Collaborators: University of Oulu
Conditions Physical Inactivity, Sedentary Behavior, Occupational Diseases, Physical Activity
Enrollment 140 participants
Start Date 2024-06
Primary Completion 2026-01 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2024-04-09